Showing results (161-170 of 197) with videos related to
Sort By:
Pageof 20
Dermatology and Therapy|February 10, 2025
Analysis of Predefined Safety Events Across Spesolimab Trials in Dermatological and Non-Dermatological ConditionsKenneth B Gordon, Yayoi Tada, Milan J Anadkat, et al.JAMA Dermatology|October 14, 2020
Effect of Risankizumab on Patient-Reported Outcomes in Moderate to Severe Psoriasis: The UltIMMa-1 and UltIMMa-2 Randomized Clinical TrialsMatthias Augustin, Jo Lambert, Carla Zema, et al.Journal of the American Academy of Dermatology|March 3, 2020
Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapiesAlan Menter, Joel M Gelfand, Cody Connor, et al.Dermatology and Therapy|August 17, 2024
Long-Term Safety of Risankizumab in Patients with Psoriatic Disease: A Comprehensive Analysis from Clinical TrialsKenneth B Gordon, Andrew Blauvelt, Hervé Bachelez, et al.Journal of the American Academy of Dermatology|October 3, 2006
Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension studyKenneth B Gordon, Richard G Langley, Craig Leonardi, et al.Journal of the American Academy of Dermatology|October 8, 2011
Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): results from analyses of infections and malignancy from pooled phase II and III clinical trialsKenneth B Gordon, Kim A Papp, Richard G Langley, et al.Dermatology and Therapy|July 30, 2024
Deucravacitinib Improves Patient-Reported Outcomes in Patients with Moderate to Severe Psoriasis: Results from the Phase 3 Randomized POETYK PSO-1 and PSO-2 TrialsApril W Armstrong, Matthias Augustin, Jennifer L Beaumont, et al.Journal of the American Academy of Dermatology|November 19, 2025
Joint position statement from the National Psoriasis Foundation Medical Board and the International Psoriasis Council on routine testing for latent tuberculosis infection prior to and during treatment of psoriasis patients with interleukin 17 or interleukin 23 inhibitorsAndrew Blauvelt, Bruce E Strober, Guy S Eakin, et al.Archives of Dermatology|December 17, 2003
A randomized trial of etanercept as monotherapy for psoriasisAlice B Gottlieb, Robert T Matheson, Nicholas Lowe, et al.Dermatology and Therapy|January 20, 2022
Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge StudyJeffrey J Crowley, Richard G Langley, Kenneth B Gordon, et al.Pageof 20